Florida Is Testing Whether “Therapy First” Becomes “Medication Last” f – Good Machine

TL;DR

Florida’s Department of Health issued non-binding guidance on 24 July cautioning against psychotropic medication for children aged 5–17 with depression, anxiety, ADHD and behavioural disorders, except in emergencies.
It asks clinicians to start with a broader assessment and, for mild symptoms, psychotherapy and behavioural supports before medication.
That is not a medication ban. Clinicians can still prescribe when medication is clinically appropriate and medically necessary.
The decisive fact is implementation: Florida says more than 400,000 children and young people have emotional, behavioural or developmental issues, but only about half can access services.
The policy’s real test is therefore not whether clinicians value sleep, family stress, movement and therapy. They do. It is whether those supports arrive in time for the children who need them.

Florida has issued a two-page guidance statement that tries to change the order of operations in youth mental-health care: examine the child’s circumstances first; consider psychotherapy, behavioural supports and physical-health factors; be cautious about psychiatric medication.

That sounds, at first glance, like a conventional plea for better care. In several respects, it is. The Florida Department of Health guidance, reported by WUSF and independently confirmed by the Miami Herald and the USA Today Network’s Florida Today, calls for a comprehensive medical, mental-health and physical evaluation. It points clinicians to sleep, screen time, unstructured play, exercise, diet, family stressors and possible underlying medical conditions. It recommends psychotherapy before medication for mild symptoms.

The more consequential sentence is the first one: Florida’s surgeon general recommends against psychotropic drugs for children aged 5–17 for conditions including anxiety, depression and attention-deficit-related disorders.

That is broader than saying medication should not be the only intervention. It is a state-level attempt to change the default frame around care. And it arrives in a system where the state itself acknowledges that access to behavioural-health services is incomplete.

The policy is not a ban. The capacity question is still real.

The first correction matters. The guidance is not legally binding. It does not prohibit a paediatrician, psychiatrist or other qualified clinician from prescribing. Florida officials say medication remains appropriate when clinically necessary, and the guidance carves out emergencies. Families should not stop, taper or change a young person’s medication because of a news headline; any adjustment belongs with the prescribing clinician.

The second correction matters more. “Therapy first” is not the same thing as “therapy available.”

Florida’s own behavioural-health access page says the state has more than 400,000 children and young people with emotional, behavioural and developmental issues, while only about half can access services. It also acknowledges a shortage of child and adolescent mental-health providers, which pushes many families back to primary-care clinicians.

That produces an uncomfortable but practical policy equation:

Comprehensive assessment + prompt therapy + clinical follow-up = a genuine whole-child pathway.
Comprehensive assessment + unavailable therapy + cautious prescribing = a longer route to treatment.

The first can improve care. The second can turn a well-intended clinical principle into delay.

What Florida is actually changing

The guidance is best understood as a default-setting document, not a new standard of law. It tells clinicians to be wary of reaching for medication before understanding the child’s environment, medical history and supports. It favours psychotherapy and evidence-based behavioural management; it also tells clinicians to consider whether an existing medication can be gradually reduced or discontinued, rather than stopped abruptly.

Some of that is uncontroversial. Good child and adolescent mental-health care already includes assessment, family context, school functioning, therapy, monitoring and shared decision-making. Medication should not be a substitute for psychosocial care simply because a 15-minute appointment is easier to schedule than a course of therapy.

But conditions grouped under “mental health” are not interchangeable. The clinical pathway for a child with mild anxiety is not the pathway for a teenager with severe depression, suicidal risk, debilitating obsessive-compulsive symptoms, or ADHD that is seriously impairing learning and daily functioning. A policy that speaks broadly about depression, anxiety and ADHD creates an obvious risk: families may hear a general warning as a claim that medication is generally inappropriate.

That is not what the evidence base says. The American Academy of Child and Adolescent Psychiatry has said that, when clinically appropriate and properly monitored, psychiatric medications can be safe, effective and, for some children, lifesaving. Its response to the federal “deprescribing” push also warned against public claims that broadly challenge established diagnoses and evidence-based treatment.

The mature position is not “medication good” or “medication bad.” It is more demanding: the diagnosis, severity, co-occurring conditions, therapy access, family preference, treatment response and safety risk determine the sequence.

The hidden bottleneck: who delivers the alternative?

Florida’s guidance asks for more of exactly the work its system struggles to supply: longer assessments, child-specialist input, psychotherapy, parent training, coordinated school support and follow-up.

That does not make the aspiration wrong. It makes delivery load-bearing.

The state’s response has been to build a Pediatric Behavioral Health Collaborative and regional hubs designed to help primary-care practices access training, tele-consultation and referral networks. That is the infrastructure a therapy-first model needs. But the existence of the program is also an admission of the underlying constraint: not every child can see a child psychiatrist, psychologist or therapist when the need first appears.

The policy will be judged by three measurements that Florida has not yet made central to the announcement:

Time to assessment: How long does a child wait for a comprehensive evaluation after a parent or school raises a concern?
Time to evidence-based therapy: How long until an appropriate clinician can actually begin treatment, not merely accept a referral?
Clinical outcomes during the wait: Are symptoms, school attendance, emergency presentations, medication use and safety outcomes improving or deteriorating?

If those numbers improve, Florida can reasonably claim that it moved care upstream. If they worsen, the policy will have shifted the rhetoric without expanding the service.

Where the hype breaks

There are two tempting but false stories here.

The first is that Florida has forbidden psychiatric care for children. It has not. The guidance is advisory, and clinicians retain prescribing discretion.

The second is that asking about sleep, food, exercise, screen use, family strain and school life is somehow a radical alternative to mental-health treatment. It is not. Those are clinically relevant factors, and they should be part of a thoughtful assessment. They are also not a substitute for treatment when a young person has a condition that requires therapy, medication, crisis intervention or several of those together.

A child cannot reliably exercise their way out of severe depression. A parent cannot screen-limit their way out of acute suicidality. And a family on a months-long therapy waitlist has not been offered a meaningful alternative merely because a policy says therapy should come first.

Who is affected — and who benefits from the argument

Children and families carry the immediate risk. Clearer assessment and real access to therapy could reduce unnecessary or poorly monitored prescribing. But broad anti-medication messaging can also make families second-guess treatment that is helping their child.

Primary-care clinicians are placed in the difficult middle. They often see children first because specialist capacity is thin. The guidance asks them to perform more comprehensive assessment and coordination, while the referral system around them remains uneven.

Child psychiatrists, psychologists and therapists become the scarce resource that determines whether this is a better-care policy or a rationing policy.

Insurers and Medicaid managed-care plans are the quieter decision-makers. They control networks, authorisation processes and reimbursement rules that determine whether therapy is reachable in practice. Any serious evaluation of Florida’s policy should examine their provider-network adequacy and referral completion rates, not only prescription counts.

Political advocates benefit from the clean story: pills versus healthy living. It travels well. It is also not how careful paediatric mental-health care works.

What this means for families and practitioners

For parents and carers

Do not make medication changes based on the guidance alone. Ask the current prescriber about benefits, side effects, alternatives and what would warrant a change.
Request a written care plan that names the working diagnosis, symptom severity, therapy recommendation, school supports, safety plan where relevant, and follow-up date.
If therapy is recommended, ask for a specific referral and a backup pathway if the first provider has no availability. “Try therapy” is not a plan without an appointment.
If a young person is in immediate danger or at risk of self-harm, use emergency services or local crisis support. This guidance does not replace urgent evaluation.

For clinicians and policy watchers

Track referral completion, not just referral creation.
Publish median waits for paediatric behavioural-health assessment and therapy by region, payer and urgency.
Separate outcomes for mild presentations from moderate-to-severe illness. A policy that works for one group can harm another if applied as a universal rule.
Treat prescription declines as an ambiguous metric. Fewer prescriptions can mean better non-drug care, unmet need, or both. Outcomes settle the question.

Uncertainty ledger

Florida has not yet shown whether the guidance will change prescribing patterns, payer behaviour or appointment availability.
The guidance is advisory; its operational force will depend on uptake by clinicians, health systems, insurers and families.
Statewide, comparable data on therapy wait times and referral completion are the missing measures. They would materially strengthen or weaken this analysis.
The document’s broad language leaves open how consistently clinicians will distinguish mild cases from children whose symptoms require timely medication alongside therapy and support.

Bottom Line

Florida is not banning psychiatric medication for young people. It is attempting to move child mental-health care toward fuller assessment and more psychosocial support before medication becomes the default.

That goal is defensible. But it has a non-negotiable condition: therapy, specialist advice and follow-up must be available when the child needs them. Until Florida can demonstrate that capacity, “therapy first” is not a clinical achievement. It is a promise whose failure mode is medication last.

Sources

Tier 1 — Primary / official: Florida Department of Health: Behavioural Health. State-reported access and workforce context.
Tier 1 — Professional body: American Academy of Child and Adolescent Psychiatry: Statement on Psychiatric Medications and Children’s Mental Health. Clinical evidence and safety framing.
Tier 2 — Public media: WUSF: Ladapo issues new Florida guidance on children’s psychiatric medications, 28 July 2026. Guidance scope, date, recommendations and non-emergency framing.
Tier 2 — Regional newspaper: Miami Herald: Florida advises against most psychotropic drugs for kids, 28 July 2026. Independent confirmation and agency response.
Tier 2 — Statewide reporting: Florida Today / USA Today Network: Florida’s top doctor warns about anxiety, depression meds for kids, 28 July 2026. Guidance language and practitioner context.